Effective June 23, 2025, certain nationalities applying for mid- to long-term residence in Japan must submit a “Certificate of Non-Tuberculosis” (TB-Free Certificate) during their Certificate of Eligibility (CoE) or visa application. This requires undergoing a “Pre-Entry Tuberculosis Screening” (JPETS) at a medical institution overseas designated by the Japanese government before applying for a CoE.
This rule will initially apply to nationals from the Philippines, Nepal, Vietnam, Indonesia, Myanmar, and China. Affected individuals are advised to allow additional time for the new medical requirements when planning their move to Japan.
Japan has introduced the JPETS due to a rise in tuberculosis (TB) cases among foreign nationals. Nationals from countries with high incidence of TB must provide proof of being TB-free before entering Japan for mid- to long-term stays.
The requirement applies to nationals from the Philippines, Nepal, Vietnam, Indonesia, Myanmar and China, including Digital Nomad visa holders and their dependents newly arriving in Japan as mid- to long- term residents.
Exceptions:
Nationality | Start Date for JPETS Appointment | Date of implementation for mandatory submission of TB-Free Certificate* |
Philippines
Nepal | March 24, 2025(Tentative) | June 23, 2025(Tentative) |
Vietnam | May 26, 2025(Tentative) | September 1, 2025(Tentative) |
Indonesia
Myanmar China | To be announced once decided | To be announced once decided |
*Applicable to those who apply for CoE or entry visa from the implementation date onwards.
The TB-Free Certificate must be submitted in these scenarios:
For employers:
For individuals:
Employers and individuals should factor the new JPETS requirements into relocation timelines and prepare proactively to avoid delays.
The JPETS system has been announced and is set to be implemented starting March 2025. However, some key details – such as the list of the designated institutions and the exact implementation dates for nationals of Indonesia, Myanmar and China – are still pending. Additionally, the potential impact of this system on application procedures, such as immigration processing timelines, remain unclear.
At Vialto Partners, we are closely monitoring updates as they become available and will provide more updates once the details are released.
For a deeper discussion on the above, please reach out to your Vialto Partners point of contact, or alternatively:
Noriyuki Tominaga
Partner
Jia Ee
Director
Shiho Okada
Manager
Zoila Mundell
Associate
Simply follow our Vialto Alerts page on LinkedIn and posts will be displayed on your feed. To ensure you don’t miss one, once you’re on our LinkedIn page, click on the bell icon under the banner image to manage your notifications.
Further information on Vialto Partners can be found here: www.vialtopartners.com
Vialto Partners (“Vialto”) refers to wholly owned subsidiaries of CD&R Galaxy UK OpCo Limited as well as the other members of the Vialto Partners global network. The information contained in this document is for general guidance on matters of interest only. Vialto is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information is provided “as is”, with no guarantee of completeness, accuracy, timeliness or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability and fitness for a particular purpose. In no event will Vialto, its related entities, or the agents or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this document or for any consequential, special or similar damages, even if advised of the possibility of such damages.
©2025 Vialto Partners. All Rights Reserved.
2025年6月23日より、特定の国籍を有する者のうち中長期在留者として日本に滞在することを希望する者を対象として、在留資格認定証明書(CoE)交付申請時または査証申請時の「結核非発病証明書」の提出が義務化されます。これにより、CoE交付申請前に日本国政府が指定する国外の医療機関において「入国前結核スクリーニング(JPETS)」の受診が必要となります。
本制度は、フィリピン、ネパール、ベトナム、インドネシア、ミャンマー、中国の国籍を有する者を対象に、順次適用される予定です。対象者については、JPETS受診のための時間を考慮し余裕ある入国計画を策定されるようご注意ください。
日本における外国籍の結核患者数が増加している状況を鑑み、日本政府はJPETS制度の開始を決定しました。日本における結核患者数が多い国の国籍を有する者が日本において中長期間在留しようとする場合、日本入国前に、結核を発病していないことの証明書を提出することが義務化されます。
フィリピン、ネパール、ベトナム、インドネシア、ミャンマー、中国のいずれかの国籍を有する者のうち、中長期在留者またはデジタルノマドビザを有する者もしくはその扶養家族として日本に入国しようとする者。
ただし、以下のいずれかに該当する場合は対象外となります。
対象国籍 | JPETS健診の受付開始 | 結核非発病証明書
提出義務の適用* |
フィリピン
ネパール | 2025年3月24日(予定) | 2025年6月23日(予定) |
ベトナム | 2025年5月26日(予定) | 2025年9月1日(予定) |
インドネシア
ミャンマー 中国 | 開始決定次第公表予定 | 開始決定次第公表予定 |
*提出義務適用日以降にCoE交付申請、査証申請を行う場合に適用されます。
結核非発病証明書は、以下の申請時に提出が必要です。
雇用主においては、以下の点にご留意ください。
対象国籍者においては、以下の点にご留意ください。
雇用主および対象国籍者は、今後、新しく始まるJPETS制度により求められる手続きに要する時間を考慮したスケジュールの策定など、赴任・来日スケジュールに遅延が生じないよう積極的な対応が求められます。
JPETS制度の開始が発表され、2025年3月から実施されます。しかし、本制度については、指定医療機関リストやインドネシア、ミャンマー、中国の国籍者への具体的な適用開始日など、いくつかの情報についてまいまだ公表されていません。また、本制度の開始により入管の審査期間など、入管での申請手続きにどのような影響が生じるかわからない点もあります。
Vialto Partnersでは、引き続き最新情報の収集を行い、詳細がわかり次第発表いたします。
より詳しい情報は、Vialtoパートナーズの担当者までお問い合わせください:
冨永 紀之
Partner
Jia Ee
Director
岡田 志帆
Manager
Zoila Mundell
Associate
Vialtoパートナーズの詳細はこちらをご覧ください
Simply follow our Vialto Alerts page on LinkedIn and posts will be displayed on your feed. To ensure you don’t miss one, once you’re on our LinkedIn page, click on the bell icon under the banner image to manage your notifications.
Further information on Vialto Partners can be found here: www.vialtopartners.com
Vialto Partners (“Vialto”) refers to wholly owned subsidiaries of CD&R Galaxy UK OpCo Limited as well as the other members of the Vialto Partners global network. The information contained in this document is for general guidance on matters of interest only. Vialto is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information is provided “as is”, with no guarantee of completeness, accuracy, timeliness or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability and fitness for a particular purpose. In no event will Vialto, its related entities, or the agents or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this document or for any consequential, special or similar damages, even if advised of the possibility of such damages.
© 2025 Vialto Partners. All rights reserved.